Abeona Therapeutics Inc.
NASDAQ:ABEOBiotechnology
+$0.06 today
- Market cap
- $156.01M
- Beta
- 1.35
- P/E (TTM)
- 4.9
- EPS (TTM)
- $1.17
Volume 1.71M
Average 1.12M
ABEO Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Abeona Therapeutics Inc.NASDAQ: ABEO
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 21.1% from a year ago
Other current liabilities stood at $2.62M at the end of Q1 FY2026, up 21.1% from a year earlier and down 53.5% from the prior quarter. Over 3 fiscal years it compounded at +26.3% a year.
Context
- Other current liabilities amounted to 1.3% of total assets at the end of Q1 FY2026, down 0.9 pp from a year earlier.
- Other current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +21.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 5.64M USD
- Year-over-year change
- +26.5%
- 4-year CAGR
- +33.1%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.64M | +26.5% |
| FY2024 | 2024-12-31 | 4.46M | +20.8% |
| FY2023 | 2023-12-31 | 3.69M | +31.9% |
| FY2022 | 2022-12-31 | 2.8M | +55.9% |
| FY2021 | 2021-12-31 | 1.79M | — |
Other Current Liabilities vs competitors
How ABEO compares with its peers on the latest reported figures
- ABEO's Mar 2026 other current liabilities of $2.62M is the 7th highest of the 10 companies compared; the peer median is $3.64M.
- Its year-over-year change of +21.1% is the 6th highest of 10, against a peer median of +29.6%.
- Other current liabilities amounts to 1.3% of total assets for ABEO, versus a peer median of 2.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $40.16M | +340.2% | +7.4% | 20.8% | |
| Mar 2026 | $5.49M | -13.6% | +19.8% | 2.2% | |
| Mar 2026 | $5.41M | +170.2% | +7.7% | 2.4% | |
| Mar 2026 | $4.86M | +268.5% | +29.8% | 3.3% | |
| Mar 2026 | $3.64M | -4.8% | -3.9% | 2.7% | |
| Mar 2026 | $3.31M | +44.2% | +25.9% | 1.5% | |
| Mar 2026 | $2.62M | +21.1% | +26.3% | 1.3% | |
| Mar 2026 | $2.37M | +29.6% | +132.4% | 1.0% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $15K | -6.3% | -22.0% | 0.0% |
| Mar 2026 | $0 | -100.0% | +16.2% | 0.0% | |
| Peer median (excluding ABEO) | $3.64M | +29.6% | +16.2% | 2.2% | |
Competitors are the stored peer set for ABEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 32.94M | 14.22M | 14.47M | 23.36M | 78.44M |
| Short-term Investments | 12.09M | 37.93M | 37.75M | 74.36M | 112.97M |
| Net Receivables | 3M | 188K | 2.44M | 1.65M | 6.72M |
| Inventory | 0 | 0 | 0 | 0 | 5.49M |
| Other Current Assets | 891K | 762K | 338K | 1.48M | 1.29M |
| Total Current Assets | 56.29M | 53.1M | 55.74M | 100.85M | 204.91M |
| Property, Plant & Equipment (Net) | 21.74M | 11.07M | 7.99M | 7.98M | 13.88M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.38M | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 168K | 43K | 277K | 96K | 781K |
| Total Non-current Assets | 23.29M | 11.12M | 8.27M | 8.08M | 14.66M |
| Total Assets | 79.59M | 64.21M | 64M | 108.93M | 219.57M |
| Account Payables | 4.33M | 1.81M | 1.86M | 3.44M | 7.89M |
| Short-term Debt | 0 | 0 | 0 | 5.93M | 12.22M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 296K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.79M | 2.8M | 3.69M | 4.46M | 5.64M |
| Total Current Liabilities | 16.62M | 7.78M | 13.42M | 16.59M | 29.57M |
| Long-term Debt | 0 | 0 | 0 | 13.04M | 7.81M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 13.04M | 23.82M | 31.35M | 32.01M | 18.9M |
| Total Non-current Liabilities | 20.6M | 29.67M | 35.75M | 48.31M | 30.78M |
| Total Liabilities | 37.22M | 37.45M | 49.18M | 64.9M | 60.35M |
| Common Stock | 1.47M | 177K | 265K | 457K | 550K |
| Retained Earnings | (655.64M) | (695.34M) | (749.52M) | (813.26M) | (742.08M) |
| Accumulated OCI | (27K) | (129K) | (66K) | 8K | 138K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 42.37M | 26.76M | 14.83M | 44.03M | 159.22M |
| Total Debt | 9.38M | 7.63M | 5.4M | 23.05M | 24.97M |
| Net Debt | (23.56M) | (6.59M) | (9.07M) | (309K) | (53.47M) |
Abeona Therapeutics Inc.
NASDAQ:ABEO
Intrinsic Alpha fair value
Locked
Current Price
$2.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.